Covered recipient · General Payments record
SHIRISH MADHAV GADGEEL
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$58,003.31
59 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $46,144.00 | 21 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,745.00 | 1 |
| Travel and Lodging | $4,665.75 | 15 |
| Food and Beverage | $1,431.54 | 21 |
| Education | $17.02 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $9,922.31 | 12 |
| PFIZER INC. | $8,779.31 | 4 |
| Amgen Inc. | $8,136.02 | 5 |
| AstraZeneca UK Limited | $6,288.20 | 6 |
| Daiichi Sankyo Inc. | $5,540.55 | 8 |
| Takeda Pharmaceuticals U.S.A., Inc. | $4,941.19 | 5 |
| ABBVIE INC. | $4,194.00 | 4 |
| AstraZeneca Pharmaceuticals LP | $3,533.22 | 9 |
| Gilead Sciences, Inc. | $2,870.00 | 1 |
| Janssen Scientific Affairs, LLC | $2,025.00 | 1 |
| F. Hoffmann-La Roche AG | $1,710.00 | 2 |
| Genentech USA, Inc. | $46.49 | 1 |
| Regeneron Healthcare Solutions, Inc. | $17.02 | 1 |
Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SHIRISH MADHAV GADGEEL
NPI 1033156534 · CMS profile ID 273900
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
DETROIT, MI
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1033156534?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SHIRISH MADHAV GADGEEL, NPI 1033156534, CMS profile ID 273900. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033156534?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). SHIRISH MADHAV GADGEEL, NPI 1033156534, CMS profile ID 273900. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033156534?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- SHIRISH MADHAV GADGEEL, NPI 1033156534, CMS profile ID 273900, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1033156534?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
59 matching records · $58,003.31 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–59 of 59.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $142.62 | 03/06/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078742908 | CMS |
| Janssen Biotech, Inc. | $826.35 | 02/27/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078743148 | CMS |
| PFIZER INC. | $133.68 | 02/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131587587 | CMS |
| AstraZeneca Pharmaceuticals LP | $52.39 | 02/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110533846 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.17 | 02/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110542191 | CMS |
| AstraZeneca Pharmaceuticals LP | $49.25 | 02/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110549756 | CMS |
| AstraZeneca Pharmaceuticals LP | $80.18 | 02/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110552422 | CMS |
| AstraZeneca Pharmaceuticals LP | $45.26 | 02/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110553492 | CMS |
| F. Hoffmann-La Roche AG | $570.00 | 01/01/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133112887 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $7,147.14 | 8 |
| PY2025 | Principal investigator | $1,651,253.73 | 148 |
| PY2024 | Recipient | $14,634.25 | 13 |
| PY2024 | Principal investigator | $1,727,359.50 | 245 |
| PY2023 | Recipient | $2,730.10 | 5 |
| PY2023 | Principal investigator | $1,514,832.69 | 236 |
| PY2022 | Recipient | $477.67 | 2 |
| PY2022 | Principal investigator | $2,007,709.06 | 253 |
| PY2021 | Recipient | $9,503.99 | 8 |
| PY2021 | Principal investigator | $1,945,999.89 | 175 |
| PY2020 | Recipient | $20,324.87 | 20 |
| PY2020 | Principal investigator | $593,845.08 | 78 |
| PY2019 | Principal investigator | $1,160,035.39 | 61 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
156 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $600.00 | 12/31/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination with Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412425 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $1,116.11 | 12/31/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A Phase II Trial of Pembrolizumab MK-3475 in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer NSCLC KEYNOTE-799. | No dispute reported | 06/30/2026 | 1232927359 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,000.00 | 12/23/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | DS7300-189 | No dispute reported | 06/30/2026 | 1223350713 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,550.00 | 12/23/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | DS7300-189 | No dispute reported | 06/30/2026 | 1223350715 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 12/23/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | DS7300-189 | No dispute reported | 06/30/2026 | 1223350717 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 12/23/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | DS7300-189 | No dispute reported | 06/30/2026 | 1223350719 |
| Principal investigator 1 | Genentech, Inc. | $4,598.00 | 12/03/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS | No dispute reported | 06/30/2026 | 1211544899 |
| Recipient | ABBVIE INC. | $725.00 | 12/01/2025 | Covered Recipient Physician | Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | No dispute reported | 06/30/2026 | 1202398235 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,230.00 | 12/01/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175361152 |
| Principal investigator 1 | PFIZER INC. | $29,290.30 | 11/26/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228728209 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,799.00 | 11/21/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | U31402-A-U102 | No dispute reported | 06/30/2026 | 1223350743 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 11/17/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | DS7300-127 | No dispute reported | 06/30/2026 | 1223350685 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,500.00 | 11/17/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | DS7300-127 | No dispute reported | 06/30/2026 | 1223350687 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,000.00 | 11/17/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | DS7300-127 | No dispute reported | 06/30/2026 | 1223350689 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 11/17/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | DS7300-127 | No dispute reported | 06/30/2026 | 1223350691 |
| Principal investigator 1 | PFIZER INC. | $21,054.80 | 11/04/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228730709 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,000.00 | 10/31/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | U31402-A-U102 | No dispute reported | 06/30/2026 | 1223350741 |
| Principal investigator 1 | ABBVIE INC. | $4,550.00 | 10/29/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412347 |
| Principal investigator 1 | ABBVIE INC. | $3,500.00 | 10/29/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412352 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 10/29/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412356 |
| Principal investigator 1 | ABBVIE INC. | $2,500.00 | 10/29/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412360 |
| Recipient | F. Hoffmann-La Roche AG | $2.01 | 10/29/2025 | Covered Recipient Physician | Open labelled randomized Alectinib VS crizotinib NSCLC 1L phase III trial | No dispute reported | 06/30/2026 | 1211538913 |
| Recipient | F. Hoffmann-La Roche AG | $0.53 | 10/23/2025 | Covered Recipient Physician | Open labelled randomized Alectinib VS crizotinib NSCLC 1L phase III trial | No dispute reported | 06/30/2026 | 1211538916 |
| Recipient | F. Hoffmann-La Roche AG | $0.47 | 10/23/2025 | Covered Recipient Physician | Open labelled randomized Alectinib VS crizotinib NSCLC 1L phase III trial | No dispute reported | 06/30/2026 | 1211538919 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,206.60 | 10/14/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | U31402-A-U103 | No dispute reported | 06/30/2026 | 1223350761 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $11,050.00 | 10/14/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | U31402-A-U103 | No dispute reported | 06/30/2026 | 1223350763 |
| Principal investigator 1 | Genmab U.S., Inc. | $186.25 | 10/14/2025 | Non-covered Recipient Entity HENRY FORD HEALTH SYSTEM | A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1235930610 |
| Principal investigator 1 | Genmab U.S., Inc. | $77,457.50 | 10/14/2025 | Non-covered Recipient Entity HENRY FORD HEALTH SYSTEM | A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1235930613 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,000.00 | 10/09/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | U31402-A-U201 | No dispute reported | 06/30/2026 | 1223350747 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,507.00 | 10/09/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | U31402-A-U201 | No dispute reported | 06/30/2026 | 1223350749 |
| Principal investigator 1 | ABBVIE INC. | $1,404.00 | 09/29/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412330 |
| Principal investigator 1 | ABBVIE INC. | $780.00 | 09/19/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412308 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 09/19/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412312 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 09/19/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412316 |
| Principal investigator 1 | Genentech, Inc. | $5,868.30 | 09/12/2025 | Covered Recipient Teaching Hospital Henry Ford West Bloomfield Hospital | EIH study with DLL3 CD3 4 1BBL TCE in SCLC and NEC | No dispute reported | 06/30/2026 | 1211545044 |
| Principal investigator 1 | Genentech, Inc. | $11,489.40 | 09/12/2025 | Covered Recipient Teaching Hospital Henry Ford West Bloomfield Hospital | EIH study with DLL3 CD3 4 1BBL TCE in SCLC and NEC | No dispute reported | 06/30/2026 | 1211545049 |
| Principal investigator 1 | Genentech, Inc. | $1,311.00 | 09/12/2025 | Covered Recipient Teaching Hospital Henry Ford West Bloomfield Hospital | EIH study with DLL3 CD3 4 1BBL TCE in SCLC and NEC | No dispute reported | 06/30/2026 | 1211545052 |
| Principal investigator 1 | Genentech, Inc. | $1,750.00 | 09/12/2025 | Covered Recipient Teaching Hospital Henry Ford West Bloomfield Hospital | EIH study with DLL3 CD3 4 1BBL TCE in SCLC and NEC | No dispute reported | 06/30/2026 | 1211545056 |
| Principal investigator 1 | Genentech, Inc. | $780.00 | 09/12/2025 | Covered Recipient Teaching Hospital Henry Ford West Bloomfield Hospital | EIH study with DLL3 CD3 4 1BBL TCE in SCLC and NEC | No dispute reported | 06/30/2026 | 1211545059 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $21,800.00 | 09/04/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | DS7300-189 | No dispute reported | 06/30/2026 | 1223350711 |
| Principal investigator 1 | Genmab U.S., Inc. | $116.00 | 08/27/2025 | Covered Recipient Teaching Hospital Henry Ford West Bloomfield Hospital | A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1235923783 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,200.00 | 08/21/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER | No dispute reported | 06/30/2026 | 1184128530 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $800.00 | 08/21/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER | No dispute reported | 06/30/2026 | 1184128532 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $275.60 | 08/21/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER | No dispute reported | 06/30/2026 | 1184128534 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,000.00 | 08/21/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER | No dispute reported | 06/30/2026 | 1184128536 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,300.00 | 08/21/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER | No dispute reported | 06/30/2026 | 1184128538 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,154.00 | 08/21/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER | No dispute reported | 06/30/2026 | 1184128540 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $7,013.52 | 08/19/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | U31402-A-U103 | No dispute reported | 06/30/2026 | 1223350759 |
| Principal investigator 1 | Genentech, Inc. | $4,598.00 | 08/19/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS | No dispute reported | 06/30/2026 | 1211544868 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,000.00 | 08/18/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | DS7300-127 | No dispute reported | 06/30/2026 | 1223350683 |
| Principal investigator 1 | PFIZER INC. | $7,600.00 | 08/14/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228788935 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $93,558.81 | 08/04/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | U31402-A-U103 | No dispute reported | 06/30/2026 | 1223350757 |
| Principal investigator 1 | ABBVIE INC. | $3,250.00 | 08/01/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412223 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 08/01/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412228 |
| Principal investigator 1 | ABBVIE INC. | $6,000.00 | 08/01/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412232 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 08/01/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412236 |
| Principal investigator 1 | ABBVIE INC. | $3,000.00 | 08/01/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412242 |
| Principal investigator 1 | ABBVIE INC. | $21,800.00 | 08/01/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412247 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 08/01/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412249 |
| Principal investigator 1 | Genmab U.S., Inc. | $5,968.00 | 07/25/2025 | Covered Recipient Teaching Hospital Henry Ford West Bloomfield Hospital | A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1235923779 |
| Principal investigator 1 | Eli Lilly and Company | $43,170.00 | 07/17/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A PHASE 1A/1B STUDY OF THE PAN-KRAS INHIBITOR LY4066434 IN PARTICIPANTS WITH KRAS MUTANT SOLID TUMORS | No dispute reported | 06/30/2026 | 1187877673 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,090.00 | 07/17/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER | No dispute reported | 06/30/2026 | 1184128510 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,510.00 | 07/10/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175361180 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,148.75 | 07/10/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER | No dispute reported | 06/30/2026 | 1184128508 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,586.00 | 07/07/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175361288 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $170,317.97 | 06/27/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer | No dispute reported | 06/30/2026 | 1185548241 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $5,197.00 | 06/25/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | 101623 | No dispute reported | 06/30/2026 | 1252496753 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,500.00 | 06/25/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | 101623 | No dispute reported | 06/30/2026 | 1252496755 |
| Principal investigator 1 | Genmab U.S., Inc. | $7,000.00 | 06/24/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1235923753 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $4,358.07 | 06/19/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A Phase 1/2 Trial of MRTX849 in Combination With TNO155 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL 2 | No dispute reported | 06/30/2026 | 1236530079 |
| Principal investigator 1 | Genentech, Inc. | $9,580.20 | 06/18/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II | No dispute reported | 06/30/2026 | 1211544673 |
| Principal investigator 1 | Genentech, Inc. | $20,356.75 | 06/12/2025 | Covered Recipient Teaching Hospital Henry Ford West Bloomfield Hospital | Ph I Ib II of TIGIT aPDL 1 | No dispute reported | 06/30/2026 | 1211545012 |
| Principal investigator 1 | Genentech, Inc. | $32,129.80 | 06/12/2025 | Covered Recipient Teaching Hospital Henry Ford West Bloomfield Hospital | Ph I Ib II of TIGIT aPDL 1 | No dispute reported | 06/30/2026 | 1211545016 |
| Principal investigator 1 | Genentech, Inc. | $1,024.90 | 06/12/2025 | Covered Recipient Teaching Hospital Henry Ford West Bloomfield Hospital | Ph I Ib II of TIGIT aPDL 1 | No dispute reported | 06/30/2026 | 1211545029 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $423.75 | 06/12/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER | No dispute reported | 06/30/2026 | 1184128502 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $978.00 | 05/28/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | U31402-A-U103 | No dispute reported | 06/30/2026 | 1223350755 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 05/27/2025 | Covered Recipient Teaching Hospital Henry Ford West Bloomfield Hospital | Ph I Ib II of TIGIT aPDL 1 | No dispute reported | 06/30/2026 | 1211544990 |
| Principal investigator 1 | Genentech, Inc. | $700.00 | 05/27/2025 | Covered Recipient Teaching Hospital Henry Ford West Bloomfield Hospital | Ph I Ib II of TIGIT aPDL 1 | No dispute reported | 06/30/2026 | 1211544995 |
| Principal investigator 1 | Genentech, Inc. | $1,412.00 | 05/27/2025 | Covered Recipient Teaching Hospital Henry Ford West Bloomfield Hospital | Ph I Ib II of TIGIT aPDL 1 | No dispute reported | 06/30/2026 | 1211544999 |
| Principal investigator 1 | Genentech, Inc. | $2,400.00 | 05/27/2025 | Covered Recipient Teaching Hospital Henry Ford West Bloomfield Hospital | Ph I Ib II of TIGIT aPDL 1 | No dispute reported | 06/30/2026 | 1211545004 |
| Principal investigator 1 | Genentech, Inc. | $674.00 | 05/27/2025 | Covered Recipient Teaching Hospital Henry Ford West Bloomfield Hospital | Ph I Ib II of TIGIT aPDL 1 | No dispute reported | 06/30/2026 | 1211545021 |
| Principal investigator 1 | Genentech, Inc. | $9,224.10 | 05/27/2025 | Covered Recipient Teaching Hospital Henry Ford West Bloomfield Hospital | Ph I Ib II of TIGIT aPDL 1 | No dispute reported | 06/30/2026 | 1211545032 |
| Principal investigator 1 | Genentech, Inc. | $7,991.00 | 05/27/2025 | Covered Recipient Teaching Hospital Henry Ford West Bloomfield Hospital | Ph I Ib II of TIGIT aPDL 1 | No dispute reported | 06/30/2026 | 1211545036 |
| Principal investigator 1 | Genentech, Inc. | $750.00 | 05/27/2025 | Covered Recipient Teaching Hospital Henry Ford West Bloomfield Hospital | Ph I Ib II of TIGIT aPDL 1 | No dispute reported | 06/30/2026 | 1211545040 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8,142.24 | 05/22/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | U31402-A-U103 | No dispute reported | 06/30/2026 | 1223350753 |
| Principal investigator 1 | Incyte Corporation | $6,138.70 | 05/14/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240475209 |
| Principal investigator 1 | Genentech, Inc. | $39,050.00 | 05/13/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS | No dispute reported | 06/30/2026 | 1211544830 |
| Principal investigator 1 | Genentech, Inc. | $39,050.00 | 05/13/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS | No dispute reported | 06/30/2026 | 1211544834 |
| Principal investigator 1 | ABBVIE INC. | $3,688.00 | 04/28/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412165 |
| Principal investigator 1 | Amgen Inc. | $20,643.68 | 04/23/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors | No dispute reported | 06/30/2026 | 1246637730 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,394.90 | 04/23/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | DS7300-127 | No dispute reported | 06/30/2026 | 1223350681 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $327.60 | 04/18/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | U31402-A-U102 | No dispute reported | 06/30/2026 | 1223350737 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,309.00 | 04/18/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | U31402-A-U102 | No dispute reported | 06/30/2026 | 1223350739 |
| Principal investigator 1 | PFIZER INC. | $5,000.00 | 04/16/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228780256 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $18,330.74 | 04/15/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutatio | No dispute reported | 06/30/2026 | 1236530071 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,000.00 | 04/09/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | DS7300-189 | No dispute reported | 06/30/2026 | 1223350701 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,000.00 | 04/09/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | DS7300-189 | No dispute reported | 06/30/2026 | 1223350703 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $400.00 | 04/09/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | DS7300-189 | No dispute reported | 06/30/2026 | 1223350705 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,000.00 | 04/09/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | DS7300-189 | No dispute reported | 06/30/2026 | 1223350707 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 04/09/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | DS7300-189 | No dispute reported | 06/30/2026 | 1223350709 |
| Principal investigator 1 | Amgen Inc. | $21,513.63 | 04/08/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300) | No dispute reported | 06/30/2026 | 1246637728 |
| Principal investigator 1 | Genentech, Inc. | $5,754.00 | 04/07/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | B FAST BLOOD FIRST ASSAY SCREENING TRIAL UMBRELLA STUDY BFAST BLOOD FIRST ASSAY SCREENING TRIAL | No dispute reported | 06/30/2026 | 1211544687 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,725.00 | 04/07/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175361411 |
| Principal investigator 1 | Genmab U.S., Inc. | $7,428.22 | 04/04/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1235923749 |
| Principal investigator 1 | Genentech, Inc. | $29,796.00 | 04/01/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | RO7247669 PLUS PLATINUM BASED CX VERSUS PEMBROLIZUMAB PLUS PLATINUM BASED CX IN 1L NSCLC Ph2 | No dispute reported | 06/30/2026 | 1211544843 |
| Recipient | F. Hoffmann-La Roche AG | $300.83 | 03/31/2025 | Covered Recipient Physician | B FAST BLOOD FIRST ASSAY SCREENING TRIAL UMBRELLA STUDY BFAST BLOOD FIRST ASSAY SCREENING TRIAL | No dispute reported | 06/30/2026 | 1211538905 |
| Recipient | F. Hoffmann-La Roche AG | $3,402.92 | 03/31/2025 | Covered Recipient Physician | Real-world Characteristics and Survival Outcomes of Patients with Metastatic ALK Fusion-positive Solid Tumors Treated with Standard-of-care Therapies | No dispute reported | 06/30/2026 | 1211538909 |
| Recipient | F. Hoffmann-La Roche AG | $380.74 | 03/31/2025 | Covered Recipient Physician | RO7247669 PLUS PLATINUM BASED CX VERSUS PEMBROLIZUMAB PLUS PLATINUM BASED CX IN 1L NSCLC Ph2 | No dispute reported | 06/30/2026 | 1211538923 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,250.00 | 03/28/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab MEDI4736 and domvanalimab AB154 compared with durvalumab plus placebo in adults with locally advanced Stage III | No dispute reported | 06/30/2026 | 1185548245 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,000.00 | 03/27/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | U31402-A-U201 | No dispute reported | 06/30/2026 | 1223350745 |
| Principal investigator 1 | ABBVIE INC. | $2,063.00 | 03/26/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412125 |
| Principal investigator 1 | ABBVIE INC. | $4,784.00 | 03/26/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412129 |
| Principal investigator 1 | ABBVIE INC. | $2,267.00 | 03/26/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412133 |
| Principal investigator 1 | ABBVIE INC. | $5,784.00 | 03/26/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412137 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 03/14/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | DS7300-127 | No dispute reported | 06/30/2026 | 1223350693 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 03/14/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | DS7300-127 | No dispute reported | 06/30/2026 | 1223350695 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,000.00 | 03/14/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | DS7300-127 | No dispute reported | 06/30/2026 | 1223350697 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,500.00 | 03/14/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | DS7300-127 | No dispute reported | 06/30/2026 | 1223350699 |
| Principal investigator 1 | ABBVIE INC. | $2,514.00 | 03/12/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412113 |
| Principal investigator 1 | ABBVIE INC. | $2,267.00 | 03/12/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412117 |
| Principal investigator 1 | ABBVIE INC. | $4,784.00 | 03/12/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412121 |
| Principal investigator 1 | PFIZER INC. | $1,344.00 | 03/12/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228784038 |
| Principal investigator 1 | ABBVIE INC. | $36,050.00 | 03/07/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | M24-536 - A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | No dispute reported | 06/30/2026 | 1202412099 |
| Principal investigator 1 | ABBVIE INC. | $2,267.00 | 03/03/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412088 |
| Principal investigator 1 | ABBVIE INC. | $2,267.00 | 02/27/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412052 |
| Principal investigator 1 | ABBVIE INC. | $3,072.00 | 02/27/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412055 |
| Principal investigator 1 | ABBVIE INC. | $2,825.00 | 02/27/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412059 |
| Principal investigator 1 | ABBVIE INC. | $2,514.00 | 02/27/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412063 |
| Principal investigator 1 | ABBVIE INC. | $5,099.00 | 02/27/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412067 |
| Principal investigator 1 | ABBVIE INC. | $2,063.00 | 02/27/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412072 |
| Principal investigator 1 | ABBVIE INC. | $2,764.00 | 02/27/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412077 |
| Principal investigator 1 | ABBVIE INC. | $2,063.00 | 02/27/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412080 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 02/21/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240475189 |
| Principal investigator 1 | Incyte Corporation | $800.00 | 02/21/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240475197 |
| Principal investigator 1 | Incyte Corporation | $1,200.00 | 02/21/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240475201 |
| Principal investigator 1 | Incyte Corporation | $750.00 | 02/21/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240475205 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $24,199.81 | 02/20/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | U31402-A-U103 | No dispute reported | 06/30/2026 | 1223350751 |
| Principal investigator 1 | Janssen Research & Development, LLC | $50,073.00 | 02/13/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175361344 |
| Principal investigator 1 | Genentech, Inc. | $2,300.00 | 02/12/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II | No dispute reported | 06/30/2026 | 1211544678 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,084.00 | 02/06/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175361298 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,941.00 | 02/06/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175361309 |
| Principal investigator 1 | PFIZER INC. | $4,524.00 | 02/05/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS | No dispute reported | 06/30/2026 | 1228770618 |
| Recipient | Amgen Inc. | $2,334.64 | 02/01/2025 | Covered Recipient Physician | Practical Management of Adverse Events in Patients Receiving Tarlatamab, a DLL3-targeted Bispecific T-cell Engager Immunotherapy, for Previously Treated Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1246636816 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,067.00 | 01/30/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | DS1062-A-U202 | No dispute reported | 06/30/2026 | 1223350661 |
| Principal investigator 1 | ABBVIE INC. | $2,764.00 | 01/29/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination with Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412014 |
| Principal investigator 1 | ABBVIE INC. | $5,360.00 | 01/29/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination with Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412018 |
| Principal investigator 1 | ABBVIE INC. | $4,731.00 | 01/29/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination with Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202412022 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $8,004.00 | 01/29/2025 | Covered Recipient Teaching Hospital Henry Ford West Bloomfield Hospital | EIH study with DLL3 CD3 4 1BBL TCE in SCLC and NEC | No dispute reported | 06/30/2026 | 1211544952 |
| Principal investigator 1 | Incyte Corporation | $2,500.00 | 01/27/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240475192 |
| Principal investigator 1 | Genentech, Inc. | $2,211.00 | 01/21/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | B FAST BLOOD FIRST ASSAY SCREENING TRIAL UMBRELLA STUDY BFAST BLOOD FIRST ASSAY SCREENING TRIAL | No dispute reported | 06/30/2026 | 1211544683 |
| Principal investigator 1 | AstraZeneca UK Limited | $135,075.03 | 01/17/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A Phase 1 Open label Dose escalation and Dose expansion study to evaluate the safety to evaluate the safety tolerability Pharmacokinetics Immunogenicity and Antitumor activity of MEDI5752 in subjects with advanced solid tumors | No dispute reported | 06/30/2026 | 1185548243 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $27,080.20 | 01/15/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | No dispute reported | 06/30/2026 | 1236530075 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,900.00 | 01/07/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER | No dispute reported | 06/30/2026 | 1184128460 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 01/07/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER | No dispute reported | 06/30/2026 | 1184128462 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 01/07/2025 | Covered Recipient Teaching Hospital HENRY FORD HOSPITAL | A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER | No dispute reported | 06/30/2026 | 1184128464 |
| Principal investigator 1 | Amgen Inc. | $292,522.50 | 01/02/2025 | Covered Recipient Teaching Hospital Henry Ford Hospital | A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | No dispute reported | 06/30/2026 | 1246637734 |